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Objective
To ascertain the spatial and temporal relation of wound hyp-
oxia to the cell types involved, expression of selected angio-
genic cytokines, the proliferative status of cells in the wound
site, and angiogenesis.
Summary Background Data
Hypoxia is considered to drive the angiogenic response by
upregulating angiogenic cytokines observed during wound
healing. But this correlation has not been shown on a cell-to-
cell basis in vivo because of limitations in measuring tissue
PO2 at the cellular level.
Methods
Using punch biopsy wounds in rats as a wound healing
model, the distributions of vascular endothelial growth factor,
transforming growth factor-beta, tumor necrosis factor-alpha,
and pimonidazole adducts (as a hypoxia marker) were fol-
lowed immunohistochemically during the healing process.
Results
Hypoxia was absent on day 1 after wounding, even though
angiogenesis and maximal expression of cytokines were ob-
served in the wounds. Hypoxia peaked in the granulation tis-
sue stage at day 4 and correlated with increased cellularity
and cellular proliferation. Hypoxia started to decrease after
day 4 and was limited to the remnant blood vessels and epi-
thelial layer in the scar tissue.
Conclusions
Induction of angiogenic cytokines early during wound healing
may be due to triggering mechanisms other than hypoxia.
Alternatively, the unique pattern of development and decline
of cellular hypoxia as wound cellularity and proliferation re-
gress suggest its involvement in initiating vascular regression
during the later stages of healing.
Tissue hypoxia is considered a major signal that initiates
and regulates angiogenic processes such as wound healing
and tumor growth.1–3 Hypoxia has been shown (in vitro) to
induce several major cytokines such as vascular endothelial
growth factor (VEGF),4 transforming growth factor-beta
(TGFb),5 tumor necrosis factor-alpha (TNFa),6 and inter-
leukin-87 from a wide variety of cells involved in tissue
repair, including fibroblasts, endothelial cells, and macro-
phages. During wound healing, tissue PO2 is considered to
be low at the center of the wound, but it increases as the
wound heals.8–10Wound-induced hypoxia, as suggested by
the in vitro data, is thought to be a major determinant of all
phases of wound healing by regulating cellular prolifera-
tion, cell migration, and extracellular matrix protein synthe-
sis through the induction of cytokines and diverse intracel-
lular signaling pathways. In vivo studies have demonstrated
decreased PO2 in wounds,
9–11 suggesting that conditions
favorable to hypoxic stimulation of cytokine production
exist.12,13These studies of wound tissue PO2 have provided
useful information on the kinetics of change in oxygenation
after wounding. However, the methods have measured over-
all average tissue PO2, whereas it is known that the diffusion
distance of oxygen is on the order of a few tens of mi-
crons.14,15 To elucidate the relation between wound hyp-
oxia, cytokine expression, and cellular responses to wound-
ing, we used immunohistochemical methods that allowed us
to evaluate these responses on a cell-to-cell basis. The
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object of our study was to ascertain the spatial and temporal
relation of wound hypoxia to the cell types involved, ex-
pression of selected angiogenic cytokines, the proliferative
status of cells in the wound site, and angiogenesis.
Pimonidazole hydrochloride belongs to a group of com-
pounds known as 2-nitroimidazole hypoxia markers that
form protein adducts under conditions of low oxygen ten-
sion (i.e.,#10 mmHg) by the action of cellular nitroreduc-
tases.16,17 The introduction of immunochemical reagents
that recognize marker adducts18 allowed the nonradioactive
detection of tissue hypoxia.19–21Although originally devel-
oped for use in animal tumors22,23and human tumors,24–26
pimonidazole hydrochloride has also been applied to the
study of hypoxia and hypoxia-associated pathophysiologic
changes in normal rat liver and kidney.27–30 Of particular
interest to the present study is the binding of pimonidazole
to suprabasal cells in epithelial structures, including skin.31
This binding is consistent with radiobiologic data that indi-
cate that the skin is hypoxic.32 The binding of pimonidazole
to skin epithelium serves as a useful positive control in the
present study of wound healing. Another advantage of the
immunohistochemical hypoxia marker approach is that it
measures cellular events with spatial resolution at the cell
level without physically disturbing the tissue during the
accumulation of the hypoxia signal. This is essential to the
present study, and no other assay can do this in vivo.
Validation of the immunohistochemical technique has been
carried out in rodent tumors and human tumor xenografts
tumors where correlations between pimonidazole adduct
formation, oxygen electrode measurements, and radiation
response have been demonstrated.23,33In a discussion of the
scope and limitation of pimonidazole as a hypoxia marker,23
it was noted that the bioreductive activation of pimonida-
zole was not dependent on specialized enzymes, nor does
the concentration of P450 cytochrome enzymes in the
perivascular region of rat livers, for example, override the
oxygen dependence of pimonidazole activation. A cell type
of specific interest to the present study is the macrophage
and its bioreductive properties in terms of the oxygen-
dependent activation of 2-nitroimidazole binding. Although
relatively little appears to be known about this topic, Olive34
has shown that host macrophages in rodent tumors behave
as tumor cells with respect to binding hypoxia markers in
the sense that binding occurred only in macrophages that
were in hypoxic regions of the tumors.
We report the absence of pimonidazole adduct formation
in the wound site and surrounding normal skin at day 1 after
wounding, indicating the absence of tissue regions with
PO2 # 10 mmHg. Hypoxia marker intensity peaked at day
4 after wounding, which coincided with the greatest cellu-
larity and proliferation. Hypoxia diminished as the cellular-
ity of the wounds regressed and mature scar tissue was
generated by day 8. In contrast, hypoxia-inducible cytokines
such as VEGF, TGFb, and TNFa exhibited maximal im-
munoreactivity at day 1, a time point where we saw no
evidence of hypoxia. These results suggest there are likely
to be signals present other than hypoxia that initiate tissue
repair and angiogenesis during the early time points after
wounding. Hypoxia reached its maximal intensity in gran-
ulation tissue at a critical juncture in the healing process
when apoptosis and remodeling were being initiated. This
pattern of development of hypoxia suggests that it may play
a role in triggering the apoptosis and remodeling of the
granulation tissue, as opposed to providing the initial stim-
ulus for proangiogenic cytokine production in the early
phases of wound healing.
METHODS
The Duke Institutional Animal Care and Use Committee
approved all animal protocols.
Wounds
Fisher 344 female rats from Charles River Laboratories
(Raleigh, NC) were anesthetized with intraperitoneal injec-
tions of pentobarbital (40 mg/kg) and ketamine (70 mg/kg),
then shaved and depilated using Nair (Carter-Wallace, New
York, NY). Sixteen 5-mm punch biopsy wounds were made
in the dorsal skin immediately after depilation. The normal
rat skin served as unwounded skin controls. Wounds were
harvested at days 1, 2, 4, 6, and 8 while the animals were
anesthetized. Two rats were killed at each time point by
intravenous pentobarbital overdose, and the experiments
were performed in triplicate. On average, 8 to 10 wounds
were harvested at each time point. Of these, only four or five
were sectioned. For hypoxia marker,$20 wounds were
used for staining purposes for each time point. For the rest
of the investigative work, 8 to 10 wounds were used in
immunohistochemistry for each time point. Tissues were
either snap-frozen using OCT in liquid nitrogen and kept at
280°C or fixed in 10% neutral buffered formalin for par-
affin embedding for immunohistochemistry.
Immunohistochemistry
Immunohistochemistry was carried out using procedures
described by Hsu et al.35 Briefly, paraffin-embedded tissues
were sectioned (5 microns) and antigen retrieval was per-
formed using citrate buffer from Biogenex (San Ramon,
CA). Tissues were treated with primary antibody against
tissue transglutaminase (1:10; TG100; nonreactive to factor
XIIIa, unpublished data) and VEGF3 (1:100; Neomarkers,
Fremont, CA), ED1-macrophage marker (MCA341; 1:100);
Serotec, Oxford, UK), pan-specific TGFb (AB-100-NA,
1:100) and rat anti-TNFa (AB-510-NA, 1:100; R&D, Min-
neapolis, MN), Ki-67 (1:100, NCL-Ki67p; Novocastra Lab-
oratories, Newcastle-upon-Tyne, UK), and rabbit poly-
clonal antisera to pimonidazole protein adducts (1:10,000,
supplied by J.A. Raleigh). Secondary and tertiary antibodies
were provided in a kit (314KLD; Innovex, Richmond, CA),
and the location of the reaction was visualized with 3,
39-diaminobenzidine tetrahydrochloride (Sigma, St. Louis,
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MO). Slides were counterstained with hematoxylin and
mounted with cover slips. Controls for the immunohisto-
chemistry were treated with normal mouse serum (NMUS)
or mouse IgG, rabbit IgG, and goat IgG and were negative
for any reactivity. Masson’s trichrome and hematoxylin and
eosin stainings were carried out as described by Sheehan
and Hrapchak.36 The immunostaining was evaluated in a
masked fashion. The stained sections were scored on the
basis of the strength of the brown product (DAB) present.
The designations used were no staining5 2, light or weak
staining5 1, strong staining5 11, and intense staining
covering most of the cellular tissue and matrix5 111.
Pimonidazole and Hoechst 33342
Administration
Pimonidazole hydrochloride (Hydroxyprobe-1; Natural
Pharmacia International Inc., Research Triangle Park, NC;
concentration 1.0 mg/100 mL in 0.9% saline) was admin-
istered at 70 mg/kg intraperitoneally 3 hours before the
animal was killed. The tissues were then harvested and
processed for immunohistochemistry. Hoechst 33342 (bis-
benzimide; Sigma) was made at a concentration of 5 mg/mL
in 0.9% NaCl and perfused through the tail vein of anes-
thetized rats during 45 seconds for a total dose of 12 mg/kg
on days 0 and 1 after wounding only. Wounds were har-
vested within 5 minutes of Hoechst 33342 administration
and were immediately embedded in OCT and frozen. Two
rats were used for each time point. Five-micron sections
were made within 2 hours, and images were visualized with
the MPS Intravital Microscopy System (Carl Zeiss,
Hanover, MD) attached to a color camera (ZVS 3C75DE;
Optronics Eng., Goleta, CA). The images were captured




At the earliest time point at day 1 (Fig. 1A), provisional
matrix with dilated blood vessels (Fig. 2A) and inflamma-
Figure 1. Light microscopic histology with hematox-
ylin and eosin of normal rat dermal wound healing.
New epithelium (A1) is being laid down as early as day
1 after wounding (A). Neovessels (A4) and dilated ex-
isting vessels (A5) can be visualized in provisional fi-
brin matrix. Skeletal muscle cells (A2) form a border
zone (A3) between normal and wounded tissue. By
day 4 (B), the epithelial layer (B6) is complete and
granulation tissue (B7) has matured. The granulation
tissue starts to contract (C8) by day 6 (C). Scar tissue
is visible by day 8 (D9) and the remnants of granula-
tion tissue (D10) have moved down to the base of the
wound.
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tory cells (Fig. 2C) could be observed underneath a newly
generating epithelial layer. Reepithelialization was com-
pleted by day 2 after wounding. Maturation of granulation
tissue was seen by day 4 (Fig. 1B), characterized by the
presence of new blood vessels (Fig. 2B), inflammatory cells
(Fig. 2D), and collagen fibers organized into a dense con-
nective tissue. Skeletal muscle cells that previously formed
a boundary between the normal and wounded tissue at
earlier time points had moved to the base of the wound and
closed the gap created by the injury (Fig. 1B). By day 6
(Fig. 1C), granulation tissue started to contract and in-
creased in density. At day 8 (Fig. 1D), the healing was in its
final stages, with remnants of granulation tissue left at the
base of the wound. The injury site was filled with dense
collagen tissue with few blood vessels.
Hypoxia Distribution During Wound
Healing
Hypoxia was detected in the epithelial layer, sebaceous
glands, and hair follicles in unwounded skin (Fig. 3A). We
observed little immunoreactivity in wounds examined on
day 1 for the hypoxia marker (Fig. 3B). The distribution of
hypoxia in adjacent normal skin structures was ordinarily
diminished at this point compared with unwounded skin. By
day 2, the wounds started to exhibit some staining for
hypoxia marker in the newly laid epithelial layer and the
border zone between the normal and wounded tissue, a
region that was infiltrated by inflammatory and endothelial
cells (Fig. 3C). Immunoreactivity for hypoxia reached its
highest intensity on day 4 after wounding (Figs. 3D, 3E).
The keratinocytes in the epithelial layer and endothelial and
inflammatory cells in the granulation tissue and the border
zone stained intensely for hypoxia at day 4. As the healing
process progressed, collagen became more organized and
the tissue was less cellular. Hypoxia marker staining inten-
sity was diminished in the organized collagen and more
localized to the base of the wound, coinciding with residual
cellularity. At day 8, hypoxia marker staining was confined
to the limited cellular content of the scar tissue, such as
blood vessels and macrophages, and to the granulation
Figure 2. Localization of blood vessels and macro-
phages. Tissue transglutaminase was used as a
blood vessel marker. Abundant blood vessels can be
identified at day 1 (A) in the provisional fibrin matrix
and in the granulation tissue at day 4 (B). Macro-
phages, as identified by ED1 marker, invade the pro-
visional fibrin matrix (C) by day 1 and are spread
throughout the granulation tissue (D). Orientation of
the figures is shown as outer layer (OL) and wounded
tissue (WT).
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tissue at the base of the wound (Fig. 3F). The intensity of
hypoxia immunoreactivity in the epithelial layer was equiv-
alent to that in unwounded skin.
Expression of Cytokines
VEGF (Fig. 4A), TGFb, and TNFa expression showed
the same distribution as hypoxia marker binding in normal
Figure 3. Immunohistochemical evidence of hypoxia
during wound healing. In normal rat skin (A), the pi-
monidazole adducts were detected in the epithelial
layer (A1), hair follicles (A2), and sebaceous glands
(A3). At day 1 (B), we did not detect any reactivity for
the hypoxia marker in the wounded tissue. On day 2
(C), macrophages (C4) and endothelial cells (C5)
started to exhibit immunoreactivity at the border of
normal and wounded tissue. By day 4 (D, E), maximal
hypoxia reactivity was observed. The epithelial layer
(D6) and granulation tissue both were highly reactive.
Macrophages (D7) and endothelial cells (D8) in small
blood vessels could be seen with evidence of pi-
monidazole adduct formation. By day 8 (F), the immu-
noreactivity was limited to the epithelial layer, remnant
blood vessels (F9), and macrophages in the scar tis-
sue. Orientation of the figures is shown as outer layer
(OL) and wounded tissue (WT).
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rat skin (i.e., epithelial layer, sebaceous glands, and hair
follicles). On day 1 after wounding, VEGF (Fig. 4B), TGFb
(Fig. 4C), and TNFa (Fig. 4D) immunoreactivity was ob-
served in the inflammatory and endothelial cells. VEGF and
TGFb were found in the provisional fibrin matrix as well
(Figs. 4B, 4C). VEGF antigen started to decline after day 2,
and detection was limited to endothelial cells in scar tissue
and granulation tissue at the base of the wound by day 8, in
a pattern similar to the distribution of hypoxia. TGFb anti-
gen remained at a high level and was detected throughout
the healing process in the matrix, inflammatory, and endo-
thelial cells. TNFa expression continued to be similar to
that of hypoxia marker in the healing process.
Hoechst 33342 and Proliferation Marker
Ki67 Distribution in Wounds
Because we observed no hypoxia marker staining on day
1, we wondered whether this might be caused by lack of
marker drug delivery (perfusion). We used Hoechst 33342
dye extravasation in the wounds to determine whether per-
fusion was adequate. The Hoechst dye permeated the epi-
thelial layer, the sebaceous glands, the hair follicles, and the
dermis of the normal skin (Fig. 5A). We found that this dye
diffused throughout the wound tissue on day 1 (Fig. 5B).
Because proliferating cells consume oxygen at rates three
to five times higher than cells in G0,
37 we hypothesized that
the high intensity of hypoxia in granulation tissue may
result from increased consumption. We used Ki67 as a
proliferation marker, and it was detected as early as day 1 in
the endothelial and epithelial cells (Fig. 6A). The immuno-
reactivity for Ki67 was highest at day 4 (Fig. 6B); it started
to decline in intensity by day 6 and was reduced to the
remnants of granulation tissue at the base of the wound by
day 8.
The time course of these events is summarized in Table 1.
DISCUSSION
This is the first study to report the distribution of hypoxia
at the cellular level and its association with cytokine ex-
pression and endothelial and inflammatory cells during
Figure 4. Cytokine expression during wound heal-
ing. Vascular endothelial growth factor (VEGF) ex-
pression could be seen in the epithelial layer (A1),
sebaceous glands (A2), and hair follicles (A3) in nor-
mal rat skin (A). By day 1, VEGF expression was
present in endothelial cells (B4) and macrophages
(B5). Active transforming growth factor-beta expres-
sion at day 1 (C) could also be localized to endothelial
cells (C6) and macrophages. Tumor necrosis factor-
alpha (D) was predominantly detected in endothelial
cells, macrophages, and skeletal muscle cells (D7).
Orientation of the figures is shown as outer layer (OL)
and wounded tissue (WT).
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wound healing. There are two interesting and unexpected
findings of this study: the absence of hypoxia in the provi-
sional fibrin matrix at day 1, a time when cytokine expres-
sion is elevated; and peak hypoxia in granulation tissue at
day 4, a time when cellular proliferation is at its peak, which
is followed by decreased wound cellularity and wound
contraction. These results suggest that hypoxia probably
does not play a role in the initial onset of cytokine expres-
sion that occurs at 1 day after wounding. Alternatively,
hypoxia probably plays a role in the maintenance of the
angiogenic response in the granulation tissue from day 2
forward. Also, the apparent relation between peak levels of
hypoxia and the onset of decreasing cellularity seems to
indicate a more prominent role of hypoxia in the initiation
of remodeling during the healing process.
The absence of hypoxia in dermal wounds early during
healing is readily explainable. Once breakdown of the epithe-
lial barrier occurs, diffusion of air (PO2 # 120 mmHg) into the
open wound and the provisional fibrin matrix happens as long
as scab formation or reepithelialization has not taken place.
Interestingly, earlier investigators found similar results with
wound fluid chambers fitted with oxygen electrodes.8 They
reported high PO2 levels (20–30 mmHg) during the first 2 days
of healing and a gradual decline in PO2 levels down to lowest
(5–8 mmHg) at 5 to 7 days after wounding. They believed that
the elevated PO2 level found in the first 2 days was an artifact
caused by oxygen contamination from the air into the wound
chamber. We argue that this is not an artifact. We propose that
in normal dermal healing, oxygen will diffuse into the wound
site by passing through the disrupted epithelial barrier from the
surrounding air. Our strongest argument to support this hy-
pothesis is based on a comparison of hypoxia marker binding
in unwounded skin and in normal skin adjacent to the wound
site at day 1 after wounding. In unwounded skin, strong marker
binding was seen in the epithelial layer, hair follicles, and
sebaceous glands. This pattern of binding was absent in normal
skin surrounding the wound site at day 1. One could argue that
the wound itself might have created enough vascular destruc-
tion to prevent adequate perfusion. If this were true, it is
possible that the hypoxia marker drug failed to reach the target
tissues. However, the strong perivascular staining with the
Hoechst dye demonstrated that the tissue was adequately per-
fused and that the hypoxia marker would have easily reached
the target tissues. Based on this evidence, we conclude that
hypoxia is not responsible for the initial triggering of the repair
and angiogenesis cascade. Recently, Howdieshell et al38 h ve
shown that wound fluid obtained from abdominal wounds was
normoxic, although they detected high levels of cytokine
(VEGF and TGFb) expression.
Alternate pathways could initiate tissue repair and angio-
genesis during the early stages of wound healing, which are
based on the coagulation system.39,40Platelets are known to
make up the first wave of exogenous cells to appear at an
injured site.41 In addition to initiating hemostasis and coag-
ulation at the site of injury, they also contain a significant
number of cytokines and extracellular matrix proteins and
enzymes that are released from storage granules after acti-
vation. These cytokines include VEGF,42 TGFb,43 TGFa,44
and platelet-derived growth factor (PDGF).45 Such cyto-
kines could promote tissue repair and angiogenesis once
they are released. It is known that platelet depletion leads to
defective wound healing.46 This is further evidence that
Figure 5. Hoechst dye staining of normal rat skin and wounded tissue.
In normal rat skin (A), Hoechst dye stain was present in the epithelial
layer (A1), sebaceous glands (A2), and hair follicles (A3). At day 1 (B), the
wounded tissue was well perfused and the newly generating epithelial
layer (B4) and provisional fibrin matrix (B5) exhibited the nuclear stain.
Orientation of the figures is shown as outer layer (OL) and wounded
tissue (WT).
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they play a role in regulation of wound healing. Our obser-
vation that hypoxia is absent during early wound healing
even though angiogenic cytokine levels are elevated sup-
ports the role of platelets as being involved at this early time
point. Thus, regulation of cytokines during early wound
healing may be a function of the coagulation system rather
than being hypoxia-driven.
The other major event during early wound healing is the
generation of thrombin and formation of a provisional fibrin
matrix. The provisional fibrin matrix provides the essential
scaffold for the endothelial and inflammatory cells to move
into the wounded tissue. Fibrin and its degradation products
have diverse biologic effects on cells invading the provi-
sional matrix and can induce various cytokines such as
interleukin-8,47 tissue factor,48 and adhesion molecules
(ICAM)49 in those cells. This provides a second pathway for
the production of cytokines to initiate repair and angiogen-
esis during early wound healing, because tissue factor itself
can stimulate VEGF50 in cells. Thus, there seems to be a
wide array of pathways and mechanisms that may be re-
sponsible for the induction of cytokines during wound heal-
ing as an alternative to hypoxia.
The results on day 4 were also intriguing. Extensive
hypoxia marker distribution correlated well with the prolif-
eration marker Ki67, suggesting that increased oxygen con-
sumption rates in the granulation tissue were responsible for
maximal hypoxia staining. Apoptosis of endothelial cells
and myofibroblasts has been shown to be responsible for the
decrease in cellularity after the surge of proliferation during
healing episodes.51,52 This wave of apoptosis has been
associated with CD95- and p53-related pathways.53,54 The
signals that trigger these events are not well understood, but
it is well established that activation of p53-dependent apo-
ptotic pathways is triggered by hypoxia.55 Additional evi-
dence implicating hypoxia in the regulation of apoptosis
uggests that hypoxia may provide the essential signaling
pathways for initiating apoptosis during healing.56
The unique pattern of emergence of hypoxia marker
reactivity at the beginning of remodeling of wounded tissue
and its gradual decline in the remodeled tissues suggests
that the development of hypoxia may be to stimulate endo-
thelial cell and myofibroblast apoptosis. Hypoxia might
very well hold the key to the puzzle of remodeling initiation,
because its progression indicates a diminished capacity for
Figure 6. Ki67 proliferation marker expression in the
wounded tissue. At day 1 (A), endothelial cells (arrow)
could be identified as picking up the proliferation
marker. The wounded tissue at day 4 (B) had high
levels of Ki67 marker expression, indicating a high
proliferation rate in the granulation tissue. Endothelial
cells in a blood vessel were shown to be expressing
the Ki67 marker (arrow). Orientation of the figures is
shown as outer layer (OL) and wounded tissue (WT).
Table 1. IMMUNOHISTOCHEMICAL DATA
Characteristic Control
Time After Wounding (days)
1 2 4 6 8
Pimonidazole immunoreactivity EP, Sg, Hf 2 1 111 11 1
Cytokines
VEGF 111 111 11 11 1
TGFb Same as pimonidazole 111 111 111 11 11
TNFa 111 111 111 11 1
Cell proliferation 2 1 11 111 1 2
Angiogenesis 2 11 111 111 11 1
Intensity of immunoreactivity is graded as 2 none, 1 weak, 11 strong, 111 intense.
Ep, epidermis; Sg, sebaceous glands; Hf, hair follicle.
144 Haroon and Others Ann. Surg. ● January 2000
nutrient and oxygen delivery at a time that coincides with
the trimming of excess cell mass by apoptosis. This is an
exciting possibility that needs further investigation.
Chang et al9 studied the oxygenation of human wounds
and observed values in the range of 60 mmHg in un-
wounded skin. Oxygenation dropped to 40 mmHg in the
first few days after wounding and showed a gradual decline
to 30 mmHg by days 4 to 5. The authors suggested that the
decline in PO2 in the early period would be sufficient to
stimulate wound healing. Because our method of hypoxia
measurement detected only PO2 values, 10 mmHg, and we
found little evidence of hypoxia on day 1, there appears to
be a discrepancy between the earlier study and ours. The
PO2 measurements were performed by analyzing the PO2 of
fluid inside implanted Silastic catheters. By virtue of its
size, this type of device provides an estimate of the average
tissue PO2, and such measurements are likely to be influ-
enced strongly by vascular PO2 in regions immediately
adjacent to the catheter. However, values of 30 mmHg are
not really hypoxic, if one considers the oxygen tension
distribution when measured on a more microscopic scale.
Using modern polarographic methods with electrodes that
have minimal self-consumption artifact, PO2 in normal tis-
sues such as brain,57 uterus,58 skeletal muscles, and skin59
drops to,15 mmHg. Some tissues, such as retina60 nd
liver,61 exist under chronically hypoxic conditions (PO2 #
10 mmHg). One could argue that a drop from 60 to 40
mmHg might be sufficient to stimulate angiogenesis and
wound healing, but there is no direct evidence from the
literature to support this conjecture. There have been several
in vitro studies published evaluating the production and
release of proangiogenic cytokines. In general, such studies
involved a dramatic change in PO2 (room air to 10 mmHg)
during several hours. Under such conditions, cytokines such
as VEGF,62 basic fibroblast growth factor (bFGF),63
TNFa,6 and TGFb12 have been shown to be upregulated.
However, these conditions are not comparable to the 30%
drop reported by Chang et al. Studies are under way in our
laboratory that address this concern by maintaining the cells
at physiologic levels of oxygen (PO2 15–30 mmHg) for a
few cell cycles and then exposing them to hypoxia.
To summarize (Fig. 7), we have shown that there is no
hypoxia during the early events of wound healing but that it
is maximal in the most cellular phases of granulation. We
found expression of proangiogenic cytokines in the provi-
sional fibrin matrix during early wound healing, suggesting
other trigger mechanisms for induction of these cytokines at
this time point. However, the unique pattern of development
and decline of hypoxia as wound cellularity and prolifera-
tion regress suggests its involvement in initiating apoptosis
during the later stages of the healing process.
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